MX2018000696A - Anticuerpos humanizados anti-beta-amiloide piroglutamados. - Google Patents

Anticuerpos humanizados anti-beta-amiloide piroglutamados.

Info

Publication number
MX2018000696A
MX2018000696A MX2018000696A MX2018000696A MX2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A MX 2018000696 A MX2018000696 A MX 2018000696A
Authority
MX
Mexico
Prior art keywords
humanized antibodies
amyloidosis
amyloid beta
pyroglutamated
peptide
Prior art date
Application number
MX2018000696A
Other languages
English (en)
Inventor
Kleinschmidt Martin
Schilling Stephan
Rahfeld Jens-Ulrich
Piechotta Anke
Gillies Steven
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of MX2018000696A publication Critical patent/MX2018000696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)

Abstract

La invención se refiere a anticuerpos humanizados que se unen a un epítopo en N-terminal de péptido beta-amiloide (Aß N3pE) piroglutamado y a tratamiento preventivo y terapéutico de enfermedades y condiciones relacionadas con la acumulación y deposición de péptidos amiloide, tales como amiloidosis, un grupo de trastornos y anormalidades asociados con el péptido amiloide piroglutamado, tal como la enfermedad de Alzheimer, síndrome de Down, angiopatía amiloide cerebral y otros aspectos relacionados. Más específicamente, pertenece al uso de anticuerpos monoclonales humanizados para unirse al péptido beta amiloide piroglutamado en plasma, cerebro y fluido cerebroespinal para prevenir la acumulación o la deposición inversa de Aß N3pE dentro del cerebro y en varios tejidos en la periferia, y para aliviar la amiloidosis. La presente invención además pertenece a ensayos de diagnóstico para el diagnóstico de amiloidosis utilizando los anticuerpos humanizados de la invención.
MX2018000696A 2015-07-16 2016-07-15 Anticuerpos humanizados anti-beta-amiloide piroglutamados. MX2018000696A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193356P 2015-07-16 2015-07-16
US201562209650P 2015-08-25 2015-08-25
PCT/EP2016/066924 WO2017009459A2 (en) 2015-07-16 2016-07-15 Humanized antibodies

Publications (1)

Publication Number Publication Date
MX2018000696A true MX2018000696A (es) 2018-05-28

Family

ID=56411667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000696A MX2018000696A (es) 2015-07-16 2016-07-15 Anticuerpos humanizados anti-beta-amiloide piroglutamados.

Country Status (14)

Country Link
US (2) US10603367B2 (es)
EP (1) EP3322723A2 (es)
JP (2) JP7002811B2 (es)
KR (1) KR20180030653A (es)
CN (1) CN108699139B (es)
AU (1) AU2016293104B2 (es)
BR (1) BR112018000097A2 (es)
CA (1) CA2992386A1 (es)
EA (1) EA038120B1 (es)
IL (1) IL256579B2 (es)
MX (1) MX2018000696A (es)
NZ (1) NZ739181A (es)
WO (1) WO2017009459A2 (es)
ZA (1) ZA201800048B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3521308B1 (en) * 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
US20230203140A9 (en) * 2018-10-04 2023-06-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Humanised anti-n-truncated amyloid beta monoclonal antibody
CA3134785A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-.beta. and uses thereof
US20220268789A1 (en) * 2019-07-05 2022-08-25 Shimadzu Corporation Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody
EP4007773A1 (en) * 2019-08-06 2022-06-08 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP2024512855A (ja) * 2021-10-28 2024-03-21 アッヴィ・インコーポレイテッド 抗アミロイドベータ抗体及びその使用方法
CN115354048B (zh) * 2022-06-08 2024-02-02 暨南大学 阿尔茨海默病动物模型的构建方法、用途和Aβ42重组表达载体
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320942B1 (en) * 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
WO2011002494A1 (en) * 2009-07-01 2011-01-06 University Of Tenessee Research Foundation Use of immunoglobulin heavy and light chains or fragments therof to bind to aggregated amyloidogenic proteins
JP6147665B2 (ja) * 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
BR112013023211B1 (pt) * 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
WO2012136552A1 (en) * 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ

Also Published As

Publication number Publication date
WO2017009459A2 (en) 2017-01-19
JP2018524370A (ja) 2018-08-30
AU2016293104B2 (en) 2022-08-11
CA2992386A1 (en) 2017-01-19
BR112018000097A2 (pt) 2018-09-04
EP3322723A2 (en) 2018-05-23
US10603367B2 (en) 2020-03-31
EA201890313A1 (ru) 2018-09-28
IL256579A (en) 2018-02-28
NZ739181A (en) 2023-05-26
JP2022017271A (ja) 2022-01-25
KR20180030653A (ko) 2018-03-23
CN108699139A (zh) 2018-10-23
CN108699139B (zh) 2022-06-24
US11045533B2 (en) 2021-06-29
US20200138922A1 (en) 2020-05-07
US20180140689A1 (en) 2018-05-24
EA038120B1 (ru) 2021-07-08
AU2016293104A1 (en) 2018-02-08
IL256579B2 (en) 2023-03-01
ZA201800048B (en) 2018-11-28
WO2017009459A3 (en) 2017-03-16
IL256579B (en) 2022-11-01
JP7002811B2 (ja) 2022-03-04

Similar Documents

Publication Publication Date Title
MX2018000696A (es) Anticuerpos humanizados anti-beta-amiloide piroglutamados.
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
MX356800B (es) Anticuerpo tau humanizado.
WO2019098763A3 (ko) 알파-시누클레인에 대한 항체 및 그 용도
PH12015500767A1 (en) Antibodies recognizing alpha-synuclein
MY164579A (en) Safe and functional humanized antibodies
PH12015500507A1 (en) Humanized antibodies to amyloid beta
WO2008011348A3 (en) Humanized antibody against amyloid beta
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
MX2016005050A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.
WO2016005466A3 (en) IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2017049038A3 (en) Anti-cd115 antibodies
WO2012139069A3 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
MX2020007986A (es) Anticuerpos humanizados y desinmunizados.
PH12012501882A1 (en) Humanized antibody against amyloid beta
WO2016150415A8 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
WO2016179057A8 (en) Complement c3d-binding compounds
EP4073046A4 (en) COMPOUNDS AND METHODS FOR THE DIAGNOSIS, IMAGING AND TREATMENT OF NEURODEGENERATIVE DISEASES AND CONDITIONS
EA201991020A2 (ru) Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений